Ticker Details
Insmed, Inc. Insmed Inc is a global biotechnology company. It is focused on developing novel therapies that focus primarily on lung diseases.
IPO Date:	June 1, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$34.45B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 2.80%
Avg Daily Range (30 D):	$2.63 | 1.78%
Avg Daily Range (90 D):	$3.03 | 1.86%

Institutional Daily Volume
Avg Daily Volume:	.69M
Avg Daily Volume (30 D):	1.94M
Avg Daily Volume (90 D):	2.13M

Trade Size
Avg Trade Size (Sh.):	99
Avg Trade Size (Sh.) (30 D):	52
Avg Trade Size (Sh.) (90 D):	54

Institutional Trades
Total Institutional Trades:	9,756
Avg Institutional Trade:	$5.03M
Avg Institutional Trade (30 D):	$12.25M
Avg Institutional Trade (90 D):	$18.4M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$11.83M
Avg Closing Trade (30 D):	$58.45M
Avg Closing Trade (90 D):	$88.78M
Avg Closing Volume:	187.79K

News

Apr 8, 2026 @ 5:00 PM Interstitial Lung Disease Market to Witness Accele... Source: Delveinsight

Mar 21, 2026 @ 11:19 PM This New $193 Million Bet Targets a Biotech With $... Source: Jonathan Ponciano

Jan 6, 2026 @ 10:12 PM Stock Market Today, Jan. 6: Alumis Shares Surge on... Source: Howard Smith

Dec 21, 2025 @ 3:01 PM Nike, Insmed, And Arm Are Among Top 10 Large Cap L... Source: Nabaparna Bhattacharya

Dec 13, 2025 @ 1:00 AM Annual Changes to the Nasdaq-100 Index® Source: Nasdaq

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-6.42	$-1.53	$-6.42
Diluted EPS	$-6.42	$-1.53	$-6.42
Revenue	$606.42M	$263.84M	$606.42M
Gross Profit	$483.49M	$219.62M	$483.49M
Net Income / Loss	$-1276.78M	$-328.49M	$-1276.78M
Operating Income / Loss	$-1246.77M	$-319.75M	$-1246.77M
Cost of Revenue	$122.94M	$44.22M	$122.94M
Net Cash Flow	$-44.59M	$175.68M	$-44.59M
PE Ratio

Splits
Mar 03, 2011	1:10
Jul 31, 2000	1:4